Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of the central nervous system, today announced successful completion of a Phase I clinical evaluation of its Kv3 modulator, AUT00206.
